Evidence map›Paper›PMID 42589411›Full record

ReviewInternational journal of molecular sciences2026

PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.

Elizabeth Santana Dos Santos, André Luiz Cicilini, Maria Fernanda Evangelista Simões, Maria Baz, Sandrine M Caputo, Etienne Rouleau

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elizabeth Santana Dos SantosDepartment of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-010, Brazil.ORCID 0000-0002-2038-4668
André Luiz CiciliniDepartment of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-010, Brazil.ORCID 0000-0002-7263-9925
Maria Fernanda Evangelista SimõesDepartment of Clinical Oncology, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.
Maria BazGustave Roussy Cancer Genetics Laboratory, Department of Medical Biology and Pathology, 94800 Villejuif, France.
Sandrine M CaputoDepartment of Genetics, Institut Curie, Paris Sciences and Lettres (PSL) University, 75005 Paris, France.ORCID 0000-0001-5338-9388
Etienne RouleauGustave Roussy Cancer Genetics Laboratory, Department of Medical Biology and Pathology, 94800 Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated remarkable efficacy in tumors carrying

Indexed as

Breast NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsAnimalsBRCA1 ProteinBRCA2 ProteinFemaleHomologous RecombinationHumansMaleRecombinational DNA RepairBRCA1 ProteinBRCA2 ProteinPoly(ADP-ribose) Polymerase Inhibitorsbreast cancerDNA repairhomologous recombination deficiencyHRR genesneoplasmsnon-BRCA HR genesovarian cancerpancreatic cancerPARP inhibitorsprostate cancer

Identifiers

PMID42589411
PMCPMC13466446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.